- Home
- AWH vs VRAX Comparison
AWH vs VRAX Comparison
Compare AWH & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWH
- VRAX
- Stock Information
- Founded
- AWH 1993
- VRAX 2013
- Country
- AWH United States
- VRAX United Kingdom
- Employees
- AWH N/A
- VRAX N/A
- Industry
- AWH Medical/Dental Instruments
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AWH Health Care
- VRAX Health Care
- Exchange
- AWH Nasdaq
- VRAX Nasdaq
- Market Cap
- AWH 2.9M
- VRAX 7.3M
- IPO Year
- AWH N/A
- VRAX 2022
- Fundamental
- Price
- AWH $0.15
- VRAX $1.29
- Analyst Decision
- AWH Buy
- VRAX
- Analyst Count
- AWH 2
- VRAX 0
- Target Price
- AWH $4.40
- VRAX N/A
- AVG Volume (30 Days)
- AWH 10.9M
- VRAX 194.7K
- Earning Date
- AWH 03-27-2025
- VRAX 02-05-2025
- Dividend Yield
- AWH N/A
- VRAX N/A
- EPS Growth
- AWH N/A
- VRAX N/A
- EPS
- AWH N/A
- VRAX N/A
- Revenue
- AWH $8,963,000.00
- VRAX $84,872.00
- Revenue This Year
- AWH $11.87
- VRAX $5,169.18
- Revenue Next Year
- AWH $79.10
- VRAX $66.97
- P/E Ratio
- AWH N/A
- VRAX N/A
- Revenue Growth
- AWH N/A
- VRAX 7.03
- 52 Week Low
- AWH $0.12
- VRAX $0.60
- 52 Week High
- AWH $3.81
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- AWH 30.23
- VRAX 33.99
- Support Level
- AWH $0.12
- VRAX $1.22
- Resistance Level
- AWH $0.36
- VRAX $1.84
- Average True Range (ATR)
- AWH 0.04
- VRAX 0.18
- MACD
- AWH 0.01
- VRAX -0.02
- Stochastic Oscillator
- AWH 14.00
- VRAX 9.59
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.